Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The figure also surpassed the Zacks Consensus Estimate of $44.96. Regeneron initiated a quarterly cash dividend program and declared a dividend of $0.88 per share. The dividend is payable on March ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Pharmaceuticals announced on Friday the Food and Drug Administration has issued a complete response letter regarding the ...

Regeneron Pharmaceuticals Inc. (NASDAQ ... The company also announced its first-ever dividend and authorized another $3 billion in its stock buyback program. Shares are down 42% from their ...

FDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...